21 terminated. 21 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Terminated 21 |
| Phase 1 | 7 | Terminated 7 |
| Phase 3 | 2 | Terminated 2 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Danazol, Placebo - Pulmonary Fibrosis, Telomere Shortening | Phase 2 | Terminated | The University of Queensland | 29 | 2021-09-07 | 2025-08-05 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Imsidolimab, placebo - Ichthyosis | Phase 2 | Terminated | Vanda Pharmaceuticals | 5 | 2021-01-25 | 2025-09-16 |
| HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 255 | 2020-09-28 | 2026-01-28 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 50 | 2019-12-20 | 2026-07-21 |
| Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa RGN-137, Placebo - Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa | Phase 2 | Terminated | Lenus Therapeutics, LLC | 4 | 2019-05-22 | 2022-08-22 |
| A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis | Phase 2 | Terminated | Mayne Pharma International Pty Ltd | 65 | 2019-05-01 | 2023-08-14 |
| EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 98 | 2019-04-26 | 2026-01-27 |
| FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD GT005, GT005 / Device: Orbit™ Subretinal Delivery System - Dry Age-related Macular Degeneration, Macular Degeneration | Phase 1 / Phase 2 | Terminated | Gyroscope Therapeutics Limited | 56 | 2018-12-17 | 2026-01-28 |
| A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene QR-313, Placebo - Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant | Phase 1 / Phase 2 | Terminated | Phoenicis Therapeutics | 2 | 2018-07-02 | 2021-08-25 |
| Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17) Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP) - Junctional Epidermolysis Bullosa | Phase 1 / Phase 2 | Terminated | Holostem s.r.l. | 1 | 2018-03-19 | 2022-03-07 |
| Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) diacerein 1% ointment, A placebo ointment - Epidermolysis Bullosa Simplex | Phase 2 | Terminated | Castle Creek Pharmaceuticals, LLC | 54 | 2017-06-01 | 2019-11-05 |
| Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB. Genetically corrected cultured epidermal autograft (ATMP) - Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Terminated | Holostem s.r.l. | 3 | 2017-01-30 | 2022-02-16 |
| A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-007 - Epidermolysis Bullosa Dystrophica, Recessive | Phase 1 / Phase 2 | Terminated | Castle Creek Biosciences, LLC. | 6 | 2016-07-01 | 2023-02-08 |
| Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa SD-101 dermal cream (6%) - Epidermolysis Bullosa | Phase 2 | Terminated | Scioderm, Inc. | 42 | 2014-03-26 | 2019-11-04 |
| Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS Doxorubicin, Trabectedin - Sarcoma | Phase 2 | Terminated | Grupo Espanol de Investigacion en Sarcomas | 115 | 2009-11-01 | 2015-10-27 |
| Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita danazol - Fanconi Anemia, Dyskeratosis Congenita | Phase 1 / Phase 2 | Terminated | Boston Children's Hospital | 5 | 2009-11-01 | 2019-02-19 |
Showing 20 of 21. Sign in to see all of them.
Epidermolysis Bullosa Dystrophica (4) · Anetoderma (3) · Epidermolysis Bullosa (3) · Eye Diseases (3) · Geographic Atrophy (3) · Netherton Syndrome (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Dyskeratosis Congenita (2) · Epidermolysis Bullosa, Junctional (2) · Arterial calcification of infancy (1) · Basal Cell Nevus Syndrome (1) · Carcinoma, Basal Cell (1) · Epidermolysis Bullosa Simplex (1) · Fanconi Anemia (1)
Skin Diseases (21) · Skin and Connective Tissue Diseases (21) · Congenital Abnormalities (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (17) · Skin Diseases, Genetic (17) · Connective Tissue Diseases (8) · Skin Diseases, Vesiculobullous (8) · Infant, Newborn, Diseases (6) · Keratosis (6) · Epidermolysis Bullosa (5) · Ichthyosis (5) · Abnormalities, Multiple (4) · Collagen Diseases (4)
Danazol (2) · cyclic adenosine-5'-trimetaphosphate (2) · Doxorubicin (1) · Injections (1) · Ointments (1) · Trabectedin (1) · diacerein (1) · spesolimab (1) · thymosin beta(4) (1) · trifarotene (1)
Gyroscope Therapeutics Limited (3) · Holostem s.r.l. (2) · Boehringer Ingelheim (1) · Boston Children's Hospital (1) · Castle Creek Biosciences, LLC. (1) · Castle Creek Pharmaceuticals, LLC (1) · Daiichi Sankyo (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Inozyme Pharma (1) · Lenus Therapeutics, LLC (1) · Mayne Pharma International Pty Ltd (1) · Phoenicis Therapeutics (1) · RegeneRx Biopharmaceuticals, Inc. (1) · Scioderm, Inc. (1) · Sol-Gel Technologies, Ltd. (1)
United States (14) · France (9) · United Kingdom (7) · Australia (6) · Germany (6) · Spain (5) · Austria (3) · Israel (3) · Netherlands (3) · Poland (2) · Bulgaria (1) · Canada (1) · China (1) · Italy (1) · Japan (1)
Johann W. Bauer, MD (2) · Michele De Luca, MD/Professor (2) · Andres Poveda, Ph.M. (1) · Colin A Sieff, MB.BCh (1) · David R Crockford (1) · Javier Martin Broto, PhM (1) · Keith A. Choate, MD (1) · Kurt Gunter, MD (1) · Mary Spellman, MD (1)
PMID 37314061, PMID 31215818, PMID 33750925, PMID 34857525
2008 (1), 2017 (1), 2019 (1)